This activity includes a Patient Interaction Simulation.
Program Description
The rate of obesity in the United States has more than tripled in the past 2 decades. Individuals who are obese are at greater risk for cardiovascular disease, such as atrial fibrillation (AF), and often require medications such as direct oral anticoagulants (DOACs). Non-valvular AF often occurs due to high blood pressure. It is typical for medications to be dosed adjusted based on weight, but for obese patients adipose tissue can change, making it imperative that pharmacists recognize and properly adjust weight-based dosing requirements. However, none of the medication labeling for currently approved DOACs lists dose adjustments for patients with BMI greater than 30. Pharmacists can advise physicians about limitations of use of DOACs in patients with non-valvular AF and obesity. This activity will review the pharmacokinetics and pharmacodynamics for DOACs, and equip pharmacists to assist in providing individualized patient care based on disease state, potential drug interactions, and lifestyle or diet. An interactive patient simulation will allow pharmacists to experience clinical decision making for patients with obesity who require use of DOACs.
Target audience: Health System Pharmacist, Retail Pharmacist
Type of activity: Application
Release date: July 21, 2022
Expiration date: July 21, 2023
Time to complete activity: 2.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore the pharmacokinetics and pharmacodynamics of FDA-approved dosing for apixaban, dabigatran, edoxaban, and rivaroxaban as it relates to body weight and obesity
- Analyze standards of care, efficacy, and safety data from randomized controlled trials on direct oral anticoagulants (DOACs) versus warfarin in patients with atrial fibrillation and obesity or extreme obesity
- Identify the role of the pharmacist in patient management, including supportive assessment, effective treatment decision making that considers DOACs versus warfarin, identification of patients, monitoring of response and follow-up, and adverse effect monitoring
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
